From GlobeNewswire: 2025-03-21 08:30:00

Silexion Therapeutics Corp. has completed an expanded development plan for its next-generation siRNA candidate, SIL204, to address KRAS-driven cancers. The plan will be presented at the Cancer Advocacy Group of Louisiana NeauxCancer 2025 Conference in New Orleans on March 27th-29th, 2025. The strategic plan leverages recent preclinical data and aims to maximize SIL-204’s potential across multiple delivery approaches. Silexion’s management team will present the plan and recent preclinical findings at the conference’s Innovation track on March 28th at 1:00pm. Interested investors can schedule one-on-one meetings with the company during the event.



Read more at GlobeNewswire: Silexion Therapeutics Announces Completion of Innovative